Can we predict the risk factors for switching due to ineffectiveness in the first year of therapy with bDMARD in patients with rheumatoid arthritis? Ana Martins; Sofia Pimenta; Daniela Oliveira; Rafaela Nicolau; Alexandra Bernardo; Teresa Martins Rocha; Lúcia Costa; Miguel Bernardes;

Safety of biologic and synthetic targeted therapies in patients with immune-mediated diseases: data from the BIOBADAGUAY registry Paloma de Abreu; Sonia Cabrera; Darwin Cordovilla; Lourdes Román; Cristina Brunengo; Patricia Melgarejo; Macarena Soto; Vannia Valinotti; Angelica Amarilla; Belem Acevedo; Alexis Pineda; Evelyn Leiva; Paola Pusineri; Sandra Consani; Mariela Zarza; Clyde Parodi; Zoilo Morel; Roger Rolón; Paola Jara; Raquel Aranda; Laura Martínez; Gabriela Ávila;

Comorbidities in Mexican Mestizo patients with rheumatoid arthritis: A cross-sectional study of 523 patients in a preventive cardio-rheumatology clinic Rosa I. Arvizu-Rivera; Jesus A. Cardenas-de la Garza; Valeria Gonzalez-Gonzalez; Dionicio A. Galarza-Delgado; Jose R. Azpiri-Lopez; Andrea L. Guajardo-Aldaco; Maria F. Elizondo-Benitez; Iris J. Colunga-Pedraza;